For HFpEF, what is considered a primary disease-modifying therapy?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Congestive Heart Failure Test. Access multiple choice questions and detailed explanations. Enhance your understanding of CHF and boost your confidence for the test day!

Multiple Choice

For HFpEF, what is considered a primary disease-modifying therapy?

Explanation:
The main idea is that disease-modifying therapy in HFpEF is about drugs that improve hard outcomes (like reducing hospitalizations and death) beyond just relieving symptoms. In this area, the strongest and most consistent evidence comes from SGLT2 inhibitors. Large trials in HFpEF show these drugs reduce heart-failure–related hospitalizations and cardiovascular death, with additional kidney protection, and their benefit appears independent of diabetes status. Mineralocorticoid receptor antagonists add another layer because blocking the mineralocorticoid receptor can reduce cardiac fibrosis and diastolic dysfunction, with several studies showing improved outcomes in HFpEF for selected patients. So, using SGLT2 inhibitors plus MRAs represents the best-supported disease-modifying approach for HFpEF among the options. By contrast, diuretics mainly address congestion without altering prognosis, and other drugs either lack strong HFpEF-specific outcome data or are primarily studied in HFrEF.

The main idea is that disease-modifying therapy in HFpEF is about drugs that improve hard outcomes (like reducing hospitalizations and death) beyond just relieving symptoms. In this area, the strongest and most consistent evidence comes from SGLT2 inhibitors. Large trials in HFpEF show these drugs reduce heart-failure–related hospitalizations and cardiovascular death, with additional kidney protection, and their benefit appears independent of diabetes status. Mineralocorticoid receptor antagonists add another layer because blocking the mineralocorticoid receptor can reduce cardiac fibrosis and diastolic dysfunction, with several studies showing improved outcomes in HFpEF for selected patients. So, using SGLT2 inhibitors plus MRAs represents the best-supported disease-modifying approach for HFpEF among the options. By contrast, diuretics mainly address congestion without altering prognosis, and other drugs either lack strong HFpEF-specific outcome data or are primarily studied in HFrEF.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy